Independent
Tenure on this board
3.0 yrs
Also a director at
Arrivent Biopharma Inc (AVBP)Bioage Labs Inc (BIOA)Seaport Therapeutics Inc (SPTX)
Meeting calendar
RAPP · Annual meeting · Wednesday, June 10, 2026
Rapport Therapeutics Inc
3 nominees · 2 ballot items.
Election of three Class II directors (James Healy, M.D., Ph.D.; Robert J. Perez; Raymond Sanchez, M.D.) and ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year ending December 31, 2026.
Market cap
$2.0B
1Y TSR
+173.8%
Board grade
C+
Record date
Apr 14, 2026
Filing
DEF 14A
Meeting concluded · Jun 10, 2026
Follow how the vote landed and what changed on Rapport Therapeutics Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot2
- 1
Election of Class II Directors
ManagementBoard: FORElect James Healy, M.D., Ph.D., Robert J. Perez, and Raymond Sanchez, M.D. as Class II directors, each to serve a three-year term until the 2029 annual meeting and until their successors are duly elected and qualified.
- 2
Ratification of Independent Registered Public Accounting Firm
ManagementBoard: FORRatify the appointment of PricewaterhouseCoopers LLP as Rapport Therapeutics, Inc.’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
Director elections
Nominees on the ballot3
Independent
Tenure on this board
1.7 yrs
Raymond Sanchez, M.D.
Independent
Tenure on this board
New nominee
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | TRV GP V, LLC | 14.9% | 7,135,233 | $223M |
| 2 | FMR LLC | 8.4% | 4,002,801 | $125M |
| 3 | ARCH Venture Management, LLC | 7.8% | 3,728,738 | $117M |
| 4 | FMR LLC | 6.6% | 3,166,138 | $99M |
| 5 | Capital International Investors | 6.5% | 3,097,973 | $97M |
| 6 | Cormorant Asset Management, LP | 6.2% | 2,957,521 | $93M |
| 7 | Sofinnova Investments, Inc. | 4.0% | 1,904,408 | $60M |
| 8 | JOHNSON JOHNSON | 3.7% | 1,784,517 | $56M |
| 9 | GOLDMAN SACHS GROUP INC | 3.5% | 1,680,576 | $53M |
| 10 | Polar Capital Holdings Plc | 3.4% | 1,642,461 | $51M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Rapport Therapeutics Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Anaptysbio IncANAB
Annual meeting·Aug 11, 2026·$1.8B
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.7B
Prestige Consumer Healthcare IncPBH
Annual meeting·Aug 4, 2026·$2.2B
Avanos Medical IncAVNS
Special meeting·Jul 22, 2026·$1.2B
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$724M
Haemonetics CorpHAE
Annual meeting·Jul 24, 2026·$3.4B
Reference
Frequently asked questions
- When is the Rapport Therapeutics Inc 2026 annual meeting?
- Rapport Therapeutics Inc (RAPP) holds its 2026 annual shareholder meeting on Wednesday, June 10, 2026.
- What is the record date for the Rapport Therapeutics Inc 2026 meeting?
- The record date for the Rapport Therapeutics Inc 2026 meeting is Tuesday, April 14, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Rapport Therapeutics Inc's 2026 meeting?
- The board is presenting 3 director nominees at the Rapport Therapeutics Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Rapport Therapeutics Inc 2026 meeting?
- Shareholders will vote on 2 proposals at the Rapport Therapeutics Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.